Glycopyrronium
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Glycopyrronium
Glycopyrronium: Known uses and market status in Australia
Summary
The TxGNN model has no candidate with a score of 0.99 or higher for Glycopyrronium, so there is currently no new predicted indication. The drug’s recorded uses are listed below.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 3 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| asthma | licence in another country |
| chronic obstructive pulmonary disease | licence in another country |
| sialorrhea | licence in another country |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 10059K | seebri breezhaler | Capsule containing powder for oral inhal | Valid |
Safety Considerations
Specific warnings and contraindications were not available in the data compiled for this report. Please refer to the TGA-approved Product Information (PI) for safety information.
Drug Interactions: An interaction query returned 100 records. Most listed are of Moderate severity, and a few are Minor. Examples include:
- Additive anticholinergic effects: other antimuscarinics such as aclidinium, hyoscyamine and homatropine, and sedating antihistamines such as chlorpheniramine, acrivastine and phenyltoloxamine
- Opioids and central nervous system depressants: fentanyl, alfentanil, codeine, dihydrocodeine, tramadol, loperamide and ethanol
- Others: botulinum toxin type A, amantadine, amitriptyline, acebutolol, acetylcholine (Moderate); acetaminophen and hydrochlorothiazide (Minor)
Class-level cautions from the prediction analysis:
- Antimuscarinics may precipitate angle closure or raise intraocular pressure in glaucoma. This is relevant to two of the predicted indications.
- Peripheral anticholinergic effects such as urinary retention and tachycardia still apply, although the quaternary structure limits CNS penetration.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.